Tandem Diabetes Care (NASDAQ:TNDM) Posts Earnings Results, Misses Expectations By $0.19 EPS

Tandem Diabetes Care (NASDAQ:TNDM) issued its quarterly earnings data on Wednesday. The medical device company reported ($0.44) EPS for the quarter, missing the consensus estimate of ($0.25) by ($0.19), Zacks reports. Tandem Diabetes Care had a negative return on equity of 44.19% and a negative net margin of 14.84%.

Tandem Diabetes Care Stock Up 0.7 %

NASDAQ TNDM traded up $0.25 during trading hours on Wednesday, hitting $33.59. 1,847,944 shares of the company traded hands, compared to its average volume of 998,159. The company has a debt-to-equity ratio of 1.29, a quick ratio of 2.32 and a current ratio of 2.90. The business’s 50-day moving average is $35.44 and its 200-day moving average is $36.64. The stock has a market capitalization of $2.21 billion, a price-to-earnings ratio of -17.40 and a beta of 1.32. Tandem Diabetes Care has a twelve month low of $25.78 and a twelve month high of $53.69.

Wall Street Analysts Forecast Growth

Several brokerages have issued reports on TNDM. Morgan Stanley upgraded Tandem Diabetes Care from an “equal weight” rating to an “overweight” rating and set a $45.00 price target for the company in a report on Monday, December 2nd. Citigroup lowered their target price on Tandem Diabetes Care from $57.00 to $50.00 and set a “buy” rating for the company in a research note on Wednesday, December 11th. Canaccord Genuity Group reaffirmed a “buy” rating and issued a $63.00 price target on shares of Tandem Diabetes Care in a research note on Wednesday. Barclays increased their price objective on shares of Tandem Diabetes Care from $58.00 to $60.00 and gave the stock an “overweight” rating in a research report on Friday, November 8th. Finally, Robert W. Baird cut their price objective on shares of Tandem Diabetes Care from $39.00 to $37.00 and set a “neutral” rating on the stock in a research report on Thursday, November 7th. Four analysts have rated the stock with a hold rating and fifteen have given a buy rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $54.25.

Tandem Diabetes Care Company Profile

Tandem Diabetes Care, Inc, a medical device company, designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform for managing insulin delivery and display continuous glucose monitoring sensor information directly on the pump home screen; and Tandem Mobi insulin pump, an automated insulin delivery system.